D-Allulose Inhibits Ghrelin Responses, Glucose Sensitivity, and Neuropeptide Y Neurons in the Arcuate Nucleus

Allulose and the brain

Allulose is usually talked about as a sweetener. This study suggests it may do something else entirely. Researchers tested whether D-allulose could directly affect the brain’s hunger circuits. It did.

Why the arcuate nucleus matters

The arcuate nucleus is a small part of the hypothalamus. It controls feeding behavior. Two types of neurons sit at the center of that control. NPY neurons drive hunger. POMC neurons drive satiety. Ghrelin, a hormone released by the gut, excites NPY neurons. Low glucose also excites them. That makes sense. When you are hungry, both signals point the same direction.

If a substance can quiet NPY neurons and activate POMC neurons, it shifts the balance toward fullness. That is exactly what this study looked for.

What the study did

The researchers used calcium imaging to track neuronal activity. They challenged ARC neurons with ghrelin and with low glucose. They recorded the calcium rises that normally accompany activation. Then they applied D-allulose and repeated the challenges.

They also looked at spontaneous oscillations in NPY neurons. These oscillatory calcium rises are part of how NPY neurons maintain their hunger-promoting output.

Finally, they gave D-allulose as an intracerebroventricular injection. That means directly into the brain’s ventricles. The injections happened at 20:00 and 22:00, during the early dark phase. That is a time when hunger is naturally promoted in the experimental setting.

Key findings

D-Allulose blocked the calcium rises triggered by ghrelin. It also blocked the calcium rises triggered by low glucose. Spontaneous NPY neuron activity dropped. At the same time, POMC neurons became more active. That is a two-sided effect. The authors describe it as a bidirectional regulator of the two major appetite neuron populations.

Measurement	D-Allulose effect
Ghrelin-induced [Ca2+]i rise in ARC neurons	Inhibited
Low-glucose-induced [Ca2+]i rise in ARC neurons	Inhibited
Spontaneous oscillatory [Ca2+]i rise in NPY neurons	Suppressed
POMC neuron activity	Activated
Food intake after brain injection at 20:00 and 22:00	Suppressed

The food intake finding is worth repeating. When D-allulose was delivered centrally during the early dark phase, it reduced food intake. That is a direct behavioral outcome. The neural data and the feeding data point the same way.

What this means for formulators

This paper adds something important to the allulose story. Allulose is not just a bulk sweetener with low calories. It appears to have a central mechanism that relates to energy sensing and hunger signaling.

For formulators working on meal replacements, satiety products, or reduced-calorie foods, this matters. It gives a plausible biological basis for why allulose may behave differently from other sweeteners. It also opens questions about product timing. If allulose influences ghrelin-responsive neurons, intake before a meal might be more relevant than intake during a meal. But this is still a hypothesis.

There is one big caveat. The study used direct brain injection. That does not prove that orally consumed allulose reaches these neurons in effective amounts. The oral route involves absorption, metabolism, and transport across the blood-brain barrier. Those steps are not covered in this paper. So use it as mechanistic support. Do not use it as a claim.

Questions you might ask

Can we say allulose reduces appetite in humans? Not yet. This is a mechanistic study. Human trials would be needed to confirm whether oral allulose changes appetite, fullness, or food intake through these pathways.

Is D-allulose the same as the allulose we buy? Yes. Commercial allulose is D-allulose. The study uses the same chemical form.

Does this change formulation dosage? No. This paper does not provide a dose for food products. It provides a mechanism. That is still valuable, but it is not a formulation guideline.

Where this leaves you

Allulose already has a strong position as a low-calorie sweetener. This study suggests it may also communicate with the brain’s hunger system. The mechanism is clear. The translation from brain injection to oral intake still needs to be proved. For ingredient buyers, the practical point is simple. Allulose is no longer just a sugar replacement. It is a compound with documented biological activity in the circuits that regulate eating. That is worth following.